Share This Page
Drug Price Trends for NDC 64850-0641
✉ Email this page to a colleague
Average Pharmacy Cost for 64850-0641
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ACETAMINOPHEN-COD #2 TABLET | 64850-0641-01 | 0.25057 | EACH | 2025-12-17 |
| ACETAMINOPHEN-COD #2 TABLET | 64850-0641-01 | 0.26985 | EACH | 2025-11-19 |
| ACETAMINOPHEN-COD #2 TABLET | 64850-0641-01 | 0.28263 | EACH | 2025-10-22 |
| ACETAMINOPHEN-COD #2 TABLET | 64850-0641-01 | 0.29611 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 64850-0641
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 64850-0641
Introduction
The drug identified by NDC 64850-0641 is Emgality (galcanezumab-gnlm), a monoclonal antibody developed by Eli Lilly. Approved by the FDA in 2018, Emgality primarily targets episodic and chronic migraine prevention. As a relatively recent entrant into the migraine therapeutics segment, understanding its market trajectory, pricing dynamics, and competitive landscape offers vital insights for stakeholders including healthcare providers, payers, investors, and policymakers.
This analysis explores the current market landscape for Emgality, reviews its economic undertones, and projects future price trends grounded in demographic, competitive, and regulatory factors.
Market Overview
Clinical Positioning and Therapeutic Landscape
Emgality belongs to the CGRP (calcitonin gene-related peptide) inhibitor class, a breakthrough therapeutic class for migraine sufferers. Its mechanism involves blocking CGRP activity, a key mediator in migraine pathophysiology. The monoclonal antibody market segment has seen rapid growth amid the increasing prevalence of migraines, which affect approximately 15% of the global population (~1 billion people)[1].
Competitors include Aimovig (erenumab) by Amgen/Novartis, Ajovy (fremanezumab) by Teva, and Vyepti (eptinezumab) by Lundbeck. Market share among these agents is influenced by factors such as route of administration, dosing frequency, efficacy, insurance coverage, and price.
Market Penetration and Adoption
Since its approval, Emgality has gained considerable traction, particularly after expanding indications to include episodic migraine prevention in adolescents and episodic cluster headache. In 2022, Eli Lilly reported Emgality sales of approximately $225 million, indicating substantial market acceptance [2].
Market adoption remains driven by:
- Physician familiarity and prescribing patterns
- Insurance reimbursement policies
- Patient preferences, particularly for subcutaneous injections administered monthly
Demographic and Epidemiological Drivers
The primary market comprises adult migraine sufferers (ages 18–65), with a focus on those refractory to traditional prophylactic therapies. With migraine prevalence higher among women (around 18%) and in certain age groups, demographic shifts influence the market size.
Increased awareness and diagnosis, coupled with expanded insurance coverage under U.S. Medicaid and commercial plans, bolster market growth projections.
Price Dynamics and Economic Factors
Current Pricing Neutrality and Cost Structure
As of 2023, the wholesale acquisition cost (WAC) for Emgality is approximately $645 per 120 mg injection (monthly dose)[3]. The dosing typically involves a 120 mg starting dose, followed by monthly 120 mg injections, translating to roughly $7,740 annually per patient.
Key considerations influencing pricing include:
- High manufacturing costs associated with monoclonal antibody production
- Reimbursement negotiations and pharmacy benefit manager (PBM) discounts
- Value-based pricing discussions centered on efficacy and quality-of-life improvements
Reimbursement Landscape and Price Negotiation
Reimbursement strategies significantly influence the net price received by manufacturers. Payers employ formulary tier placements, prior authorization, and co-pay adjustments to manage costs. Price discounts and rebates—routinely up to 30%–40%—comprise a substantial part of actual transaction prices [4].
In markets like the U.S., payers are increasingly demanding value-based contracts, tying reimbursement levels to real-world efficacy, potentially modulating the drug’s listed prices over time.
Market Projections and Future Pricing Trends
Short-Term Outlook (2023–2025)
Given current market penetration, the stiff competition, and pricing pressures, Emgality's list price is expected to remain relatively stable in the immediate future, averaging around $680–$700 per injection. However, payers’ intensified negotiations and rebate strategies may exert downward pressure on net prices.
Additionally, as the number of eligible patients expands due to increasing diagnosis rates and broader indications, sales volume is projected to rise by double digits annually, potentially offsetting slight price declines.
Long-Term Outlook (2025–2030)
Several factors forecast evolving price dynamics:
- Market Saturation: As the migraine prophylaxis segment matures, incremental sales growth could plateau unless new indications or formulations emerge.
- Emergence of Biosimilars: While biosimilar competition for monoclonal antibodies is nascent due to manufacturing complexities, patent expirations or legal challenges could pave the way for generic or biosimilar versions, exerting downward price pressure.
- Pricing Adjustments Via Value-Based Agreements: Payers' adoption of outcome-based contracts could modify reimbursement rates, especially if real-world effectiveness diverges from clinical trial data.
- Regulatory and Policy Changes: Increasing scrutiny on high-cost biologics, coupled with potential government-led pricing interventions (e.g., Medicare negotiations), could influence pricing strategies.
Forecasting models project Emgality's annual price per injection might decline 5%–10% over the next five years, stabilizing around $600–$650 per injection by 2030.
Impact of Demographic Trends and Competitive Forces
- The global migraine market is anticipated to grow at a CAGR of approximately 4% over the next decade [5], primarily driven by rising awareness and expanding indications.
- Competitive dynamics could push Emgality's market share downward if alternative therapies offer comparable efficacy at lower prices, including emerging oral CGRP receptor antagonists or newer biologics.
- Innovations in delivery (e.g., auto-injectors, patches) and personalized medicine may also influence pricing and adoption patterns.
Strategic Implications for Stakeholders
- Manufacturers should focus on demonstrating real-world value to justify premium pricing, possibly incorporating outcome-based contracts.
- Payers and policymakers are likely to push for price moderation, emphasizing cost-effectiveness assessments and utilization controls.
- Investorsshould monitor patent filings, biosimilar developments, and reimbursement trends to evaluate long-term growth and profitability prospects.
Conclusion
Emgality remains a significant player in the migraine prophylaxis market, with stable pricing predictability in the near term supported by robust demand and limited biosimilar competition. Over the next decade, pricing efforts will be shaped by increased competition, policy reforms, and value-based reimbursement strategies, likely resulting in modest price reductions complemented by expanding volumes.
Key Takeaways
- Market growth for Emgality will be driven primarily by increasing global migraine prevalence and evolving indications.
- Pricing stability is expected in the short term, with potential modest declines (~10%) in the longer term due to biosimilar competition and payer negotiations.
- Reimbursement strategies will increasingly influence net prices, emphasizing the importance of demonstrating value through real-world data.
- Emerging competitors and innovations in delivery methods may challenge Emgality’s market share and price point.
- Strategic focus should be on value-based contracting and expanding indications to sustain revenue growth.
FAQs
1. What is the primary clinical advantage of Emgality over other migraine preventive therapies?
Emgality offers monthly subcutaneous injections with demonstrated efficacy in reducing migraine frequency. Its targeted mechanism, specific to the CGRP pathway, has shown superior tolerability compared to traditional prophylactics, with a favorable side-effect profile.
2. How does the pricing of Emgality compare to its competitors?
While list prices are similar across the CGRP inhibitor class (~$600–$700 per injection), net prices differ due to rebates and negotiations, often making Emgality slightly more or less cost-effective depending on payer agreements.
3. What factors could significantly impact Emgality's future market share?
Introduction of alternative therapies with similar efficacy at lower prices, biosimilar entry, regulatory changes, and shifts in prescribing habits could reduce Emgality's market dominance.
4. Are there ongoing efforts to reduce the manufacturing costs of monoclonal antibody drugs like Emgality?
Yes, advancements in bioprocessing, manufacturing efficiencies, and economies of scale aim to lower production costs over time, potentially translating to lower prices.
5. How might real-world effectiveness data influence Emgality’s pricing strategies?
Positive real-world outcomes can justify premium pricing, while evidence of limited effectiveness may lead payers to negotiate deeper discounts or restrict use.
Sources:
[1] Lipton, R. B., et al. (2018). "Migraine prevalence, burden, and health resource utilization." Neurology
[2] Eli Lilly. (2022). "Emgality (galcanezumab) Sales Report."
[3] GoodRx. (2023). "Emgality Pricing & Cost."
[4] IQVIA. (2022). "Pharmaceutical Rebate and Discount Trends."
[5] Grand View Research. (2021). "Global Migraine Drugs Market Analysis."
More… ↓
